Home » Stocks » PRPH

ProPhase Labs, Inc. (PRPH)

Stock Price: $12.04 USD -0.17 (-1.39%)
Updated Jan 25, 2021 3:36 PM EST - Market open
Market Cap 148.40M
Revenue (ttm) 12.49M
Net Income (ttm) -1.61M
Shares Out 11.60M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $12.04
Previous Close $12.21
Change ($) -0.17
Change (%) -1.39%
Day's Open 11.98
Day's Range 11.49 - 12.39
Day's Volume 444,711
52-Week Range 1.20 - 16.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 3 days ago

Garden City, NY, Jan. 21, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced the closing of its previously annou...

GlobeNewsWire - 6 days ago

GARDEN CITY, NY, Jan. 18, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today the pricing of an underwritten publ...

GlobeNewsWire - 1 week ago

GARDEN CITY, NY, Jan. 15, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has commenced a proposed un...

GlobeNewsWire - 2 weeks ago

Company Exceeding Near Term Goals & Expands 2021 Testing Capacity

GlobeNewsWire - 2 weeks ago

GARDEN CITY, NY, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced that it has entered into a definiti...

GlobeNewsWire - 1 month ago

Company Expands to Meet Anticipated Demand for Increased Molecular Testing From New Business Opportunities – Aiming For Capacity to Process 50,000 Tests per Day

GlobeNewsWire - 2 months ago

DOYLESTOWN, Pennsylvania, Nov. 16, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, today announced net sales of $3.8 million ...

GlobeNewsWire - 2 months ago

DOYLESTOWN, PA , Nov. 10, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase Labs”), a diversified medical science and technology company, today announced that management w...

GlobeNewsWire - 2 months ago

DOYLESTOWN, Pennsylvania, Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today that it has completed the ...

GlobeNewsWire - 3 months ago

DOYLESTOWN, Pennsylvania, Oct. 23, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, announced today a definitive agreement to ...

GlobeNewsWire - 3 months ago

Company Enters into Consulting Agreement and Amended and Restated Promissory Note and Security Agreement with Predictive Laboratories, Inc. to Further These Plans

GlobeNewsWire - 3 months ago

DOYLESTOWN, Pennsylvania, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a diversified medical science and technology company, has engaged international investor relati...

GlobeNewsWire - 4 months ago

DOYLESTOWN, Pennsylvania, Sept. 23, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com ) today announced that it has entered into an at-the-market (“ATM”) equi...

GlobeNewsWire - 4 months ago

DOYLESTOWN, Pennsylvania, Sept. 18, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced that it has closed on a $10 million unsecured debt finan...

GlobeNewsWire - 5 months ago

DOYLESTOWN, Pennsylvania, Aug. 11, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced net sales of $3.6 million for the three months ended June...

GlobeNewsWire - 8 months ago

DOYLESTOWN, Pennsylvania, May 12, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com ) today announced net sales of $1.9 million for the three months ended Mar...

GlobeNewsWire - 10 months ago

DOYLESTOWN, Pennsylvania, March 25, 2020 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today announced its net sales were $9.9 million for the year ended Decem...

GlobeNewsWire - 1 year ago

DOYLESTOWN, PA, Nov. 20, 2019 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com), a vertically integrated manufacturer, marketer and distributor of a diversified ra...

GlobeNewsWire - 1 year ago

ProPhase Labs, Inc. (NASDAQ: PRPH, www.ProPhaseLabs.com) today reported net sales of $2.8 million for the three months ended September 30, 2019 compared to net sales of $2.4 million for the th...

About PRPH

ProPhase Labs engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pr... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jan 16, 1997
CEO
Ted William Karkus
Employees
48
Stock Exchange
NASDAQ
Ticker Symbol
PRPH
Full Company Profile

Financial Performance

In 2019, ProPhase Labs's revenue was $9.88 million, a decrease of -24.76% compared to the previous year's $13.13 million. Losses were -$3.15 million, 80.8% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ProPhase Labs stock is "Strong Buy" and the 12-month stock price forecast is 15.55.

Price Target
$15.55
Analyst Consensus: Strong Buy